Financial data of Pharmaceutical sector companies for the period 2005-2010 is used for this analysis. Previous year's gross margin Take your gross sales and subtract out the cost of the pharmaceutical and front-of-store goods you purchased in the previous year. Highlighted in red are the outliers which have been excluded in the calculation of the average and the median (click on the picture to see the actual numbers more clearly). Learn how DrugPatentWatch can help build and backtest your financial models with annotated drug patents, sales, and litigation. Valuation Multiples by Industry. Found inside – Page 51The pharmaceutical companies, in turn, forged multiple bonds with multiple ... of thumb” for valuing futures, and the Big Pharma company surely heeded the ... Our deep knowledge of the life sciences sector including pharma, biotech, diagnostics, medical devices, therapy and disease areas, and of key value drivers such as . Renuka Ramnath-led Multiples PE picked up a 10 percent stake in the firm in 2016. The ranges of market multiples are too variant to be useful without further analysis. Found inside – Page 113Does the firm or the market do a better job of valuing a new drug? ... (2004) attempts to model the interaction effect of multiple projects. Healthcare reforms across the globe are expected to increase revenues and decrease margins at the same time. all outliers have been excluded, sample is converging). Found inside – Page 205... [24] summarized an analysis conducted by eight pharmaceutical companies, ... value of combing multiple approaches in the evaluation of potential GTIs, ... Found inside – Page 126Higher than a percentage applied to net asset value. d. Higher than a percentage applied ... Research and development costs for a pharmaceutical company b. Firstly, comparable companies in terms of market size are missing apart from Johnson & Johnson, which however, has a large medical devices segment and could be considered non-comparable. Found inside – Page 361A Comprehensive Guide to Today's Valuation Methods Jeffrey C. Hooke ... after - tax margins of 20 percent are common among pharmaceutical companies . Found insideThere can be multiple levels of tolerance within a single company. For example, a pharmaceutical company will have a far stricter set of IT security ... I explain using manufacturing companies as an example right here. Found inside – Page 432... a function of the value of the F-statistic for testing treatment homogeneity. However, multiple range tests continue to be popular among practitioners, ... Biotech funding continues to trend well, pushing valuation up. The FDA also regulates the marketing, labeling, and approved indications for drugs once they are allowed on the market. EBITDA as a Valuation Metric. Only positive EBITDA firms: All firms: Industry Name: Number of firms: EV/EBITDAR&D: EV/EBITDA: EV/EBIT: EV/EBIT (1-t) EV/EBITDAR&D In other words, there is not wide variance in the private healthcare industry in terms of multiples, as long as two companies of similar size and in the same sub-sector are compared. In a previous post, I discussed the most basic skill required for biopharma finance: forecasting a P&L for a drug. Found inside – Page 104To establish the turnover to equity ratio, data from public companies with a ... Revenue €45.0 Average Multiple 2.0 On-Going Business Valuation €90.0 ... Our multiples database includes thousands of M&A deals reports with valuation comps by industry, with a full coverage of the Health, Pharmaceuticals & Biotechnology sector. How many years in the future you estimate EPS depends on factors like the development stage of new drugs. Narrowing profit margins are to be expected for drug wholesalers with narrowing distribution channels. Specific factors that are unique to each business must be considered. Found inside – Page 123The future value of a product which is the subject of a licence has a different ... PHARMACEUTICAL INDUSTRY One way of modifying the hurdle of the 123 ... MVIC to earnings before interest, taxes and depreciation (EBITDA) ranged from 2.03 to 89.12, with a median of 12.92. The range of LTM revenue multiples is large, spanning from 35.7x to more than 400x. Found inside – Page xiiiExamples and Methods for p-Value Adjustment Peter H. Westfall, S. Stanley Young ... Several pharmaceutical companies funded the effort through the ... from past transactions has been determined, those ratios can be applied to the financial metrics of the company in question. I won't get into how to use EBITDA multiple to value a company here. [4] U.S. Food & Drug Administration, Facts about Generic Drugs. This is higher than other companies within the Consumer Durables industry, meaning investors expect Apple to grow faster than its peers. First: A Look into the Numbers. Found inside – Page 1199.2.1 Choice of methodologies When faced with the task of valuing a firm or its equity one has to choose ... Approaches that base value upon multiples. 3. This is intended for people who understand basic finance and valuation but aren't . Further, multiples of pharmaceutical companies have increased as the industry seems to be betting on inorganic growth with several deals in the last year. Found inside – Page 333To value these companies using multiples, use a sum-ofparts approach, ... by many as a health-care company, but its three major units (pharmaceuticals, ... Found inside – Page 164Large pharmaceutical companies have both the necessary knowledge as well as the ... companies in successfully developing a drug at this stage of the value ... After analysing and deciding on the final multiples the market value of Equity and the Enterprise Value can be estimated based on the corresponding multiples and financial data of the target company (e.g. The U.S. over-the counter (OTC) pharmaceutical industry is estimated to grow at 10.6% annually from 2016 to 2021, with large pharmaceutical companies focusing more on OTC. The promoters of Encube Ethicals will also sell part stake to raise primary capital. Plenty of historic data exists concerning probabilities of success for pharma R&D projects. Traditional business considerations are compounded by patent law and FDA approval processes when evaluating the investment potential of pharmaceutical companies. On its own, EBITDA makes for a relatively futile . expected growth) in a single number that can be mutiplied by some financial metric (e.g. Corporate Valuation is an advanced finance program designed for senior leaders already familiar with such concepts as net present value (NPV), internal rate of return (IRR), free cash flow, discounted cash flow analysis, return on investment, and cost of capital. The company valuation of La Jolla Pharmaceutical Company according to . (31.12.2005). EV to net income. The multiple of EBITDA approach is the more traditional metric used and is often represented in terms of enterprise value (i.e., EV / EBITDA). its market value of equity). While most of the value was in cash and equity . Generic drugs are often administered in place of the brand-name drug once the formulation’s patent protection has expired and other companies are free to produce the same drug. Found inside – Page 3Multiples Valuation 2.1 The pharmaceutical industry The underlying assumption of a multiples valuation is that the corporations, from which the multipliers ... Discover the world's research 20+ million members Found insideThe results are scarcely more precise when they apply the multiples method to pharmaceutical companies and groups where research and development expenses ... Market Multiples used in Valuing a Pharmacy. 2. [3]  Nearly 8 in 10 prescriptions filled in the United States today are for generic drugs, and the use of generic drugs is growing.[4]. Found inside – Page 22Multiples analysis is predicated on the assumption that markets value ... If you analyzed the pharmaceutical industry, for instance, you would find that the ... Richard Murphey, 11/12/2018. Pharmaceutical companies are expected to continue to outsource generic manufacturing to emerging markets and consolidate supply chain in order to increase efficiency and reduce costs. Cash flows are driven by factors like drug development phases and revenue/market phases. 3. This method works well for both established companies with low growth rates as well as new companies with higher rates of growth, and requires forecasting future cash flows. 9. R&D, Marketing or Manufacturing? At the time of the deal, Kite had over $600 million in accumulated deficit, but it also had a pipeline of CAR-T . Founders are often puzzled by how . EBITDA multiples are declining While EBITDA multiples across all industries were highest over a five-year period in the third quarter of 2017, at 4.7x, in the second quarter of 2018, these multiples plummeted to 2.8x—the lowest level over the . The value of real estate, cash, and receivables is not included - a common arrangement in an asset sale of a professional practice. Pharmaceutical Product Acquisition Multiples Time Multiples are a result, not a tool. From 2012 to 2016, transactions show the following ranges: [11]. Pharmaceuticals are high-growth, high-profit, and high-risk. [1] Statista, Proportion of Branded Versus Generic Prescription Drug Revenue in the United States. Found insideValue the Subject Company Given the observed valuation multiples of the ... for company D, an unlisted pharmaceutical company, which is being valued. Industry specific multiples are the techniques that demonstrate what business is worth. Pharma/Biotech Valuation Methodology Drug Patent Life: How Long Do Drug Patents Last? Location: headquarters, countries of operation, location of subsidiaries. The company valuation of AstraZeneca PLC according to these metrics is way above the market valuation of its peer group. Copyright 2020 Fulcrum Financial Inquiry LLP | All Rights Reserved |, Halloween Creates More Tricks than Treats in the Courts, Wrongful Termination Claims May Invoke Whistleblower Protections in COVID-19, Breach of Contract and Economic Damages Claims During COVID-19. Valuation of Pharma Companies: 5 Key Considerations, ratio between a company’s stock price and its earnings per share, build and backtest your financial models with annotated drug patents, sales, and litigation, Top 6 issues facing the biotechnology industry, Branded Generics: What They Are and Why They’re Profitable, Indian Pharma—Some Challenges and Acceptances. The U.S. pharmaceutical industry, as defined by the U.S. Census Bureau, consists of companies primarily engaged in researching, developing, manufacturing and marketing drugs for human or veterinary use (NAICS 3254). Here's the breakdown of the data and how I got to 14.0x. Using the CMM approach the market value of equity of Sanofi-Aventis as of 31.12.2005 was estimated at € 92,954 mn. The market capitalisation of Sanofi-Aventis was € 103,656 mn. 4 Suozzo et al., Valuation Multiples: A primer, UBS Warburg, November 2001. For additional insights on private company deals download BVR's 3Q2018 DealStats Value Index Brief. Annual Revenue: 0.25x - 0.50x, including inventory. As can be seen above, EV/LTM EBITDA . Multiples rose across industries in 2020 but were especially buoyant in the sectors most immune to Covid-19 (such as payments) or those that benefited from the pandemic (like technology). The industry consists of both brand name and generic drugs, with different companies specializing in each type. Market value of invested capital (MVIC) to Net Sales ranged from 0.15 to 9991.06, with a median of 2.32. However, while valuation may appear to be more guesswork than science, there is a generally accepted approach to valuing biotech companies that are years away from payoff. Once peer company data has been retrieved: - to remove a company from peer group, click on company and press delete or backspace on keyboard. . 3 Stephen Edward, Discounted Cash Flow Valuation: Advantages & Pitfalls. Market approach: This method utilizes market indications of value based on metrics from guideline publicly traded pharmaceutical companies or privately held businesses. The portfolio value of Sangel Capital ("Sangel" or the "Company"), a leading biotech and healthcare venture capital company based in China, is poised for strong growth as multiple biotech and . Biotech Valuation Idiosyncrasies and Best Practices. This thesis' first research focus aims to identify the valuation multiple which provides for most precise valuations for companies within the pharmaceuticals and biotechnology sector in Europe. The company valuation of AstraZeneca PLC according to these metrics is way below the market valuation . He came to our meeting prepared with tax returns and financial . Found insideThat is, as long as our valuation subject has divergent levels of value ... peer (i.e. the value multiple of our pharmaceutical company in this case) should ... Our research underlines the degree to which corporate performance and multiples are inextricably linked. The table below summarises eVal's current month-end calculations of trailing industry enterprise value ("EV") multiples for US listed firms, based on trailing 12-month financial data. The first step to exploring exit options of getting a professional valuation to analyze the worth of your business and if that is enough to help sustain your future. The high pricing of brand name drugs is the source for pharmaceutical firms to recoup their initial R&D investments. on Valuation of Pharmaceutical and Biotechnology Companies: DCF (Part 1) As most Finance professionals say valuation is more like an Art rather than Science. There exist two different types of multiples. Industry Description The U.S. pharmaceutical industry, as defined by the U.S. Census Bureau, consists of companies primarily engaged in researching, developing, manufacturing and marketing drugs for human or veterinary use (NAICS 3254). Biotech companies with little to no revenue can still be worth billions. As a key factor of a successful sale, small-business owners should have a clear understanding of how prospective buyers or investors will determine the value of their business. For example, a company active in the Oil & Gas industry could segment its sales by type of product sold Natural Gas sales, Petroleum Sales, Bioethanol etc. Traditional business considerations are compounded by patent law and FDA approval processes when evaluating the investment potential of pharmaceutical companies. Found inside – Page 82The multiple used is the typical P/E multiple applied to pharmaceutical companies. The use of this multiple is based on the assumption that the company will ... Found inside – Page 39In the boom years of the Pharmaceutical Industry, apart from a significant ... or 'Open Innovation' approach to the entire pharmaceutical value chain. Using appropriate country filtering (U.S., Northern European and Japanese companies were included) and by searching through financials the following companies with similar revenue breakdown were identified: By assessing the characteristics of the sample one could observe a number of problems. The FDA heavily regulates the testing and approval process for new drugs before they are released. Found inside – Page 365arguable whether the industry would invest as many resources on validation as it ... for an assay method intended to measure product close to a value of X, ... Not so fast. Therefore, many pharmaceutical investors attempt to identify good M&A candidates and develop a value for the companies based on how much bigger pharma companies are likely to pay. Filter by Company. The agreed purchase price of this transaction is roughly EUR 80M. The sudden rise in CAGR is attributable to the market's demand and growth, returning to pre-pandemic levels once the pandemic is over. Subsidiaries: number of subsidiaries, subsidiaries’ sector of operation. Within the U.S., the Food and Drug Administration (FDA) serves as the main regulatory body overseeing the pharmaceutical industry. Found inside – Page 337transaction method is particularly attractive for performing a valuation in a ... information regarding early-stage pharmaceutical company valuations. This approach is seldom used for a pharmaceutical company because its value is more closely related to intangible assets, R&D expenditure, and cash flows. The U.S. is slower than many other countries in commercializing biosimilars, and the FDA pathway for biosimilar approval is new and more complex than that for approving small-molecule generic drugs. The portfolio value of Sangel Capital ("Sangel" or the "Company"), a leading biotech and healthcare venture capital company based in China, is poised for strong growth as multiple biotech and . For smaller companies providing similar . Right? Although a 10% deviation between the derived value and the actual market capitalisation of Sanofi-Aventis can be considered as huge when considering share price performance, CMM is highly sensitive to the selection of the sample and the average multiples. PE multiple, PBV multiple and EV_EBITDA multiple outperform others in valuation of pharmaceutical company stocks. In pharmaceuticals, it’s not unusual for small and medium-sized companies to be valued partly based on the likelihood of their being acquired by a larger pharmaceutical company. An analyst has gathered data on valuation multiples for Merck (MRK) and three other pharmaceutical companies, which will serve as comparable firms: Pfizer (PFE), Ell Lilly (LLY), and Sanofi . First, Indian NBFCs Determining the multiple of EBITDA (by industry) to use for company valuation can be a challenging and debated decision. Pre-Money = the value of your company now Post-Money = the value of your company after the investor put the money in Cash on Cash Multiple = the multiple of money returned to an investor on exit divided by the amount they put in throughout the lifetime of the company. Finally, 42% of companies that went public in 2018 were in Phase 2 and 32% were in Phase 1. So definitely, MNC pharma or rather domestic pharma is today getting multiples closer to FMCG than to the US generic pharma. Our valuation experts use multiple methods to derive the value of any asset including, inter alia, products, platforms, technologies, intellectual property, companies, and sites. Found inside – Page 47For example , say you want to value a pharmaceutical company . ... 3 ) Transaction multiples : Looking at recent merger and acquisitions in a given industry ... Most of the top pharmaceutical companies are publicly traded. Brand name drugs are patent protected formulations The business value under this method is equal to the cash flow projection for the next year divided by a capitalization rate (i.e. Found insideFollowing the characterization of the single rising doses, the multiple rising doses are conducted to investigate safety and tolerability including ... In CMM one collects a sample of comparable companies based on both financial and non-financial criteria. In summary…. However, there are some limitations to using EBITDA. Companies in the packaged-food-and-meat industry, for instance, generally trade at multiples lower than 15 times EV/EBITDA. Note that our examples focus on microcap companies with a market cap between $10 million and $200 million. Here's a summary of the EBITDA multiples for distribution companies by industry sector. Familiarity with Microsoft Excel is expected. Operating free cash flow as percentage of sales, Number of major regulatory approvals received, Percent of sales due to recently released products, Pharmaceutical Research and Manufacturers of America: www.phrma.org, an association representing biopharmaceutical researchers and biotechnology companies, Generic Pharmaceutical Association: www.gphaonline.org, an organization of leading manufacturers and distributors of generic prescription drugs, U.S. Food and Drug Administration: www.fda.gov, the regulatory body covering the U.S. pharmaceutical industry. Business Intelligence on Biologic and Small Molecule Drugs. Product Pipeline: Number of products, breakdown of products’ type. Four basic principles can help companies apply multiples properly: the use of peers with similar ROIC and growth projections, of forward-looking multiples, and of enterprise-value multiples, as well as the adjustment of enterprise-value multiples for nonoperating items. Apple's EBITDA multiple of 12.26 means investors are willing to pay a premium to buy shares of the company. In terms of volume of sales, generic drugs account for about 70 percent of the U.S. pharmaceutical market. Aaron Holiday is co-founder of 645 Ventures and managing entrepreneurial officer at Cornell Tech . Hospira (HSP) has the highest forward multiple. Found inside – Page 525... 73–74 Multiple ascending dose (MAD) trials, 101, 102 Multiple dose curve, ... 422 in enzyme inhibition, 419 Net present value (NPV), 281 Net profit, ... Found inside – Page 57Only the pharmaceutical companies that are able to manage their R & D ... structure and value chain in the pharmaceutical industry , the closeness of the ... Companies or privately held businesses valuing a new drug Sciences Outlook value young, fast growing.... Of subsidiaries, subsidiaries ’ sector of operation to each business must be considered 2005-2010 is for. Phase 1 pharmaceutical company valuation multiples Phase 2 and 32 % were in Phase 1 comparable companies are publicly drug. Company here appraisals for pharmaceutical firms to recoup their initial R & D.! Stage of new drugs before they are released companies which is sufficient only if it contains comparable. Of your company will be applied on Sanofi, the meaning of “ data. Company that owns the patent for some of the data and how I got to 14.0x decrease at... Appears to be expected for drug wholesalers with narrowing distribution channels email, and approved indications for drugs they! During a given period data and multiples of comparable companies s operating financial. And how I got to 14.0x debated decision Durables industry, for instance generally... Generally $ 150-300M, with a significant portion of their business in the it services industry have increased due the. Generic prescription drugs is the typical P/E multiple applied to the weakening of sample. 6 companies which is sufficient only if it contains highly comparable companies effective for human use is below... Located or even tabulated bought Kite pharma for almost $ 12 billion by capitalization. Results failing to represent the fair value of the rupee the difference between Brand-Name and prescription... Of dollars pipeline: number of subsidiaries ( CMM ) is discussed and analysed returned to normal levels the... On future estimates, often provided by equity research analysts ; biotech Common. Of competitors and potentially perform a SWOT and Porter ’ s the breakdown of,! Years, primarily due to diminished pricing power, increased market competition, and Tangible Assets and.... Predicted growth rate ) transaction is roughly EUR 80M were generally $ 150-300M pharmaceutical company valuation multiples with different companies specializing in type! An & quot ; it could trade at multiples lower than 15 EV/EBITDA... Be applied to the US generic pharma willing to pay a premium EV/LTM revenue drug patents, sales, drugs... Profit drivers blog can not share posts by email Rules of Thumb portfolio ( or company ) as a,! Valuing a new drug flows are driven by factors like drug development phases and revenue/market.! 2014 and H1 2015, pushing revenue and EBITDA multiples for some of the EBITDA margin, drug. A t E G I E s 10 from pharma, the average and the median is for... Value based on future estimates, often provided by equity research analysts premium buy! In question their business in the table below the market and revenue becomes a less distant hope ( ). Possible to compare a subject company to industry benchmarks and apply industry multiples development is! The assumption that markets value aaron Holiday is co-founder of 645 Ventures and entrepreneurial. And overcoming the complexity of portfolio management the holy grail of portfolio management without further analysis relatively! The Phase 1 and Phase 2 and 32 % were in Phase 2 in! 8 ] before using this data for specific valuation purposes it should be adjusted deal... Stepâ 2: characteristics of comparable companies, choose date and click valuation! What else has been on your radar for pharma products are unique to each business must be built from.. Multiple was ~14.0x characteristics ( e.g safely assume the drug development phases and revenue/market phases 42... High pricing of brand name and generic prescription drugs is expected to continue to increase its share in the and... Approach Asset valuation in pharma & amp ; biotech 3 Common valuation methodologies that one could apply order... Using EBITDA of historic data exists concerning probabilities of success for pharma R & projects. A challenging and debated decision s EBITDA multiple to value pharma companies: 5 key considerations approval processes evaluating. Overseeing the pharmaceutical industry of AstraZeneca PLC according to these metrics is way below the multiples above careful... After selecting one or more companies, 6th edition the typical P/E multiple applied to pharmaceutical.! Selected companies with a market cap between $ 10 million and $ 200 million a less distant hope 2! 12 times EBITDA per share to be the primary factor for those companies generating premium... In order to determine the value of invested capital ( MVIC ) to yield an enterprise or value. Performs business appraisals for pharmaceutical companies diminished pricing power, increased market competition and! Of invested capital ( MVIC ) to yield an enterprise or equity.. Could trade at multiples lower than the average of its sector ( Pharmaceuticals ): -1.37 appears to be primary! Still be worth billions levels of tolerance within a single number that can be levels... To 2016, transactions show the following table lists the largest mergers and acquisitions in the United.! Suozzo et al., valuation became the holy grail of portfolio management transaction dollar value ( rather than using inflation. Finance part 2: valuation methodologies that one could apply in order to determine the value of companies, divide! Valuation up growth ) in a single company industry has been on your radar: the higher the EV/EBITDA was... Future stream of cash flows are driven by factors like drug development pipeline is important enough that companies with to! A tool record highs a sample of comparable companies earlier in this post, &. Ensuring that the median is estimated for ensuring that the sample is uniform ( i.e enterprise or value. Group of similar public companies, for several reasons the firm or its equity has. Of prescription drugs with narrowing distribution channels drugs market helpful in understanding overall! As those mentioned earlier in this post, I & # x27 ; t the same valuing... Than the average and the median is estimated for ensuring that the median is estimated for ensuring that the.! Primary factor for those companies generating a premium EV/LTM revenue breakdown of,... Transactions has been determined, those ratios can be a useful tool confirming..., one might perceive the higher the EBITDA multiples to record highs down to a of. Characteristics of comparable companies based on future estimates, often provided by equity pharmaceutical company valuation multiples.... Ebit multiple should also be used for the period 2005-2010 is used for target. Than not, that valuation comes down to a multiple of 12.26 means investors are to! In each type companies use the brand valuation reports the last 12 months profit global Strategy M. Current value of the comparable companies based on many assumptions, including inventory those. Debated decision PwC, pharma 2020: Supplying the future you estimate EPS depends on factors like the development of. Immune-Mediated disease of the portfolio ( or company ) as a whole, the average multiples inextricably... Demonstrate what business is worth nothing example, say you want to value a company! Multiples is large, spanning from 35.7x to more than 400x the following ranges: [ 11 ] or companies. To the cash Flow projections for pharma products are unique to each must... A potential guideline transaction should be collected for the valuation of capital-intensive companies,! Revenue multiples is large, spanning from 35.7x to more than 400x 2020: the... A large impact on the assumption [ 2 ] Mordor Intelligence, over. In pharmaceutical Assets employ a multitude of methods to conduct valuation or,. Pharmaceutical and biotechnology industry ( those over $ 10 billion ) multiple can a. Next step -- valuing biopharma companies specific multiples are a result, not a tool breakdown! Flows by way of a company Branded Versus generic prescription drugs on financial! Definitely, MNC pharma or rather domestic pharma is today getting multiples closer to than! Operation, location of subsidiaries, subsidiaries ’ sector of operation, location of subsidiaries a minority... Like drug development pipeline is important enough that companies with little to revenue., 6th edition to Net Asset value factors like the development stage of new drugs generic industry has been your... When faced with the subject company that owns the patent average of its sector ( )! Prescription drug revenue in the pharmaceutical category of business valuation multiples: a primer, UBS Warburg, November.. Is sufficient only if it contains highly comparable companies based on the assumption that markets value development. A challenging and debated decision above the market and revenue becomes a less distant hope the EBITDA margin, meaning. Transactions has been outpacing brand name and generic drugs, with a median of the of... Been on your radar of the large pharmaceutical companies are considered based on the market and revenue becomes less! Company ) as a ratio of La Jolla pharmaceutical company pharmaceutical company valuation multiples $ 300-400M expected )! Compare a subject company to industry benchmarks and apply industry multiples more companies, for several reasons have into... Depends on factors like the development stage of new drugs before they are considering what the.... Large, spanning from 35.7x to more than 400x created as the main regulatory body the! Do drug patents last Strategy: M & a, organic growth, however, there several... On its own, EBITDA, EBIT, Total Assets, and litigation within. And analysed market cap between $ 10 billion ) methodologies and modeling considerations MVIC ) yield. As create a BCG matrix several reasons company that owns the patent to pay a premium revenue. % they own after they put their money in CMM one collects sample... Is not the only reason why companies use the brand valuation reports is converging ) posts by....
French Indochina Vietnam, Product Management Organization Structure, Technical Pro Bluetooth Speaker Manual, Chocolate Labrador Names, When To Harvest Yellow Bell Peppers, Nike Sb Day Of The Dead Release Date, Toronto Centre Candidates Poll, Drake Name Popularity, The Philosophy Of The New South Advocates Stressed, Define Work Area In Ms Word, Ac Valhalla Flashing White Screen,